(0.51%) 5 214.08 points
(0.85%) 39 388 points
(0.27%) 16 346 points
(0.39%) $79.57
(0.39%) $2.31
(0.55%) $2 353.10
(0.00%) $28.37
(0.85%) $993.00
(-0.28%) $0.928
(-0.19%) $10.87
(-0.21%) $0.798
(0.88%) $92.54
5 days till quarter result
(bmo 2024-05-14)
Expected move: +/- 9.96%
@ $15.49
发出时间: 15 Feb 2024 @ 04:23
回报率: -6.07%
上一信号: Feb 15 - 01:00
上一信号:
回报率: 1.51 %
Live Chart Being Loaded With Signals
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role...
Stats | |
---|---|
今日成交量 | 580 754 |
平均成交量 | 840 057 |
市值 | 1.16B |
EPS | $0 ( 2024-05-07 ) |
下一个收益日期 | ( $-0.510 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.31 |
ATR14 | $0.0190 (0.13%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-09 | Peng Katie | Buy | 35 767 | Stock Option (Right to Buy) |
2024-04-09 | Peng Katie | Buy | 26 825 | Common Stock |
2024-02-16 | Myles Edward H | Sell | 4 744 | Common Stock |
2024-02-16 | Qatanani Mo | Sell | 2 512 | Common Stock |
2024-02-16 | Parlavecchio Caryn | Sell | 3 751 | Common Stock |
INSIDER POWER |
---|
57.30 |
Last 96 transactions |
Buy: 9 442 259 | Sell: 2 434 527 |
音量 相关性
Scholar Rock Holding Corp 相关性 - 货币/商品
Scholar Rock Holding Corp 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-2.84M (0.00 %) |
EPS: | $-1.990 |
FY | 2023 |
营收: | $0 |
毛利润: | $-2.84M (0.00 %) |
EPS: | $-1.990 |
FY | 2022 |
营收: | $33.19M |
毛利润: | $23.31M (70.22 %) |
EPS: | $-2.21 |
FY | 2021 |
营收: | $18.82M |
毛利润: | $0.00 (0.00 %) |
EPS: | $-3.59 |
Financial Reports:
No articles found.
Scholar Rock Holding Corp
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of latent myostatin that has completed the Phase 3 clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is also developing a pipeline of novel product candidates with potential to transform the lives of patients suffering from a range of serious diseases, including neuromuscular disorders, cancer, and fibrosis. The company has a collaboration agreement with Gilead Sciences, Inc. to discover and develop specific inhibitors of transforming growth factor beta activation for the treatment of fibrotic diseases. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。